ArticleHaematologica2020

Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma.

Lisa C Holthof et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.